Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1Mesothelioma 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 6pembrolizumab 5fludarabine 4fludarabine phosphate 2amatuximab 2SS1(dsFv)PE38 2tocilizumab 1sotorasib 1sargramostim 1enzalutamide 1entinostat 1defactinib 1bemcentinib 1aldesleukin 1alanosine 1Tablets 1Sorafenib 1Sirolimus 1Quality of Life 1Polymerase Chain Reaction 1Pentostatin 1Pemetrexed 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1Ipilimumab 1Interleukin-12 Subunit p35 1Interferon-gamma 1Interferon-alpha 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Pentostatin × Other solid neoplasm × Clear all
NCT01362790 2019-06-06

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
55 enrolled 22 charts
GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡